FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789788400> ?p ?o ?g. }

• W2789788400 endingPage "395" @default.
• W2789788400 startingPage "387" @default.
• W2789788400 abstract "Abstract Background To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study. Aim To examine the safety and tolerability of flibanserin 100 mg once daily at bedtime in the treatment of premenopausal and naturally postmenopausal women with HSDD in a multicenter 28-week OLE study. Methods Patients entering this study received flibanserin or placebo in the double-blinded, placebo-controlled trials of premenopausal and postmenopausal women and in a pharmacokinetic study of postmenopausal women. Outcomes The primary end point of this OLE study was the incidence of adverse events (AEs). Secondary exploratory efficacy measures included the Female Sexual Distress Scale–Revised (FSDS-R) total score and FSDS-R item 13 (distress owing to low desire) score and the Female Sexual Function Index (FSFI) total score. Because the sponsor terminated the study early at discontinuation of the development of flibanserin, only descriptive statistics were calculated. Results Of the 595 patients receiving study medication, 346 and 249 patients were premenopausal and postmenopausal, respectively. The mean number of days of exposure to flibanserin was 72.8 (SD = 41.6). AEs were reported by 352 patients (59.2%), and most AEs (93.8%) were mild or moderate. The most common AEs (≥5%) were dizziness (9.6%), somnolence (8.6%), insomnia (6.2%), and nausea (5.7%). There were no flibanserin-related serious AEs and no instances of suicidal ideation. The safety profile of flibanserin was similar for premenopausal and postmenopausal women. The FSDS-R total scores and FSDS-R item 13 scores were numerically lower at weeks 4, 12, and 20 than at baseline (decrease in distress owing to low desire) for premenopausal and postmenopausal women. Mean FSFI total scores were numerically higher at weeks 4, 12, and 20 than at baseline, irrespective of menopausal status of the patients. Clinical Implications The results of this study support the safety and tolerability of flibanserin for the treatment of HSDD in premenopausal and naturally postmenopausal women. Strengths and Limitations Although this open-label study was designed to be 28 weeks long, it was discontinued early by the sponsor, and patients’ maximum duration of exposure to flibanserin was 23.9 weeks. The open-label design and lack of a placebo-controlled arm are other study limitations. Conclusion In this open-label study, flibanserin 100 mg once daily at bedtime was generally safe and well tolerated by premenopausal and naturally postmenopausal women with HSDD." @default.
• W2789788400 created "2018-03-29" @default.
• W2789788400 creator A5034061024 @default.
• W2789788400 creator A5071242400 @default.
• W2789788400 creator A5072826364 @default.
• W2789788400 creator A5079180373 @default.
• W2789788400 creator A5082693401 @default.
• W2789788400 creator A5085198081 @default.
• W2789788400 date "2018-03-01" @default.
• W2789788400 modified "2023-10-11" @default.
• W2789788400 title "Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study" @default.
• W2789788400 cites W1528212972 @default.
• W2789788400 cites W1990846924 @default.
• W2789788400 cites W2004405160 @default.
• W2789788400 cites W2037647348 @default.
• W2789788400 cites W2041624124 @default.
• W2789788400 cites W2062914812 @default.
• W2789788400 cites W2112997260 @default.
• W2789788400 cites W2120385927 @default.
• W2789788400 cites W2227626307 @default.
• W2789788400 cites W2282746037 @default.
• W2789788400 cites W2289228262 @default.
• W2789788400 cites W2327367145 @default.
• W2789788400 cites W2557355554 @default.
• W2789788400 cites W2619894939 @default.
• W2789788400 cites W2626065897 @default.
• W2789788400 doi "https://doi.org/10.1016/j.jsxm.2017.12.016" @default.
• W2789788400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29502984" @default.
• W2789788400 hasPublicationYear "2018" @default.
• W2789788400 type Work @default.
• W2789788400 sameAs 2789788400 @default.
• W2789788400 citedByCount "11" @default.
• W2789788400 countsByYear W27897884002020 @default.
• W2789788400 countsByYear W27897884002021 @default.
• W2789788400 countsByYear W27897884002022 @default.
• W2789788400 countsByYear W27897884002023 @default.
• W2789788400 crossrefType "journal-article" @default.
• W2789788400 hasAuthorship W2789788400A5034061024 @default.
• W2789788400 hasAuthorship W2789788400A5071242400 @default.
• W2789788400 hasAuthorship W2789788400A5072826364 @default.
• W2789788400 hasAuthorship W2789788400A5079180373 @default.
• W2789788400 hasAuthorship W2789788400A5082693401 @default.
• W2789788400 hasAuthorship W2789788400A5085198081 @default.
• W2789788400 hasConcept C107993555 @default.
• W2789788400 hasConcept C126322002 @default.
• W2789788400 hasConcept C142724271 @default.
• W2789788400 hasConcept C144024400 @default.
• W2789788400 hasConcept C15744967 @default.
• W2789788400 hasConcept C197934379 @default.
• W2789788400 hasConcept C204787440 @default.
• W2789788400 hasConcept C27081682 @default.
• W2789788400 hasConcept C2776710140 @default.
• W2789788400 hasConcept C2777092991 @default.
• W2789788400 hasConcept C2777877281 @default.
• W2789788400 hasConcept C2778093883 @default.
• W2789788400 hasConcept C2778375690 @default.
• W2789788400 hasConcept C2778715236 @default.
• W2789788400 hasConcept C2779366285 @default.
• W2789788400 hasConcept C29456083 @default.
• W2789788400 hasConcept C53813258 @default.
• W2789788400 hasConcept C71924100 @default.
• W2789788400 hasConceptScore W2789788400C107993555 @default.
• W2789788400 hasConceptScore W2789788400C126322002 @default.
• W2789788400 hasConceptScore W2789788400C142724271 @default.
• W2789788400 hasConceptScore W2789788400C144024400 @default.
• W2789788400 hasConceptScore W2789788400C15744967 @default.
• W2789788400 hasConceptScore W2789788400C197934379 @default.
• W2789788400 hasConceptScore W2789788400C204787440 @default.
• W2789788400 hasConceptScore W2789788400C27081682 @default.
• W2789788400 hasConceptScore W2789788400C2776710140 @default.
• W2789788400 hasConceptScore W2789788400C2777092991 @default.
• W2789788400 hasConceptScore W2789788400C2777877281 @default.
• W2789788400 hasConceptScore W2789788400C2778093883 @default.
• W2789788400 hasConceptScore W2789788400C2778375690 @default.
• W2789788400 hasConceptScore W2789788400C2778715236 @default.
• W2789788400 hasConceptScore W2789788400C2779366285 @default.
• W2789788400 hasConceptScore W2789788400C29456083 @default.
• W2789788400 hasConceptScore W2789788400C53813258 @default.
• W2789788400 hasConceptScore W2789788400C71924100 @default.
• W2789788400 hasFunder F4320306257 @default.
• W2789788400 hasFunder F4320312672 @default.
• W2789788400 hasIssue "3" @default.
• W2789788400 hasLocation W27897884001 @default.
• W2789788400 hasLocation W27897884002 @default.
• W2789788400 hasOpenAccess W2789788400 @default.
• W2789788400 hasPrimaryLocation W27897884001 @default.
• W2789788400 hasRelatedWork W1559925451 @default.
• W2789788400 hasRelatedWork W2110780516 @default.
• W2789788400 hasRelatedWork W2153753227 @default.
• W2789788400 hasRelatedWork W2576865763 @default.
• W2789788400 hasRelatedWork W2762573710 @default.
• W2789788400 hasRelatedWork W2947168830 @default.
• W2789788400 hasRelatedWork W2953114918 @default.
• W2789788400 hasRelatedWork W2975782988 @default.
• W2789788400 hasRelatedWork W2979914284 @default.
• W2789788400 hasRelatedWork W4226040825 @default.
• W2789788400 hasVolume "15" @default.
• W2789788400 isParatext "false" @default.

• next